EPO Board of Appeal issues communication on BI CRISPR/Cas9 patent hearing

The Board of Appeal of the European Patent Office (EPO) has issued new communication summarising issues that will be discussed at a hearing on whether the EPO erred in its revocation of a patent owned by the Broad Institute.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

University of California gains ground after EPO backs CRISPR patent

11 February 2020 In a victory for the University of California, the European Patent Office has affirmed a CRISPR patent issued to Emmanuelle Charpentier, the University of California, and the University of Vienna.

Europe

EPO appeals board weighs-up Broad’s CRISPR claims

14 January 2020 The first day of a landmark hearing on CRISPR ownership dealt nearly exclusively with untangling linguistic arguments, lawyers following the proceedings told LSIPR.

Europe

Broad Institute to appeal CRISPR patent revocation

17 January 2018 The Broad Institute of Harvard and MIT has said it will appeal against a decision by the European Patent Office to revoke one of its patents covering CRISPR/Cas9 technology.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

EPO Board of Appeal issues communication on BI CRISPR/Cas9 patent hearing

More on this story

Editor's picks

Editor's picks

More features